Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose
In: Blood, Jg. 142 (2023-11-28), Heft 1, Number 1 Supplement 1, S. 1011-1011
serialPeriodical
Zugriff:
Background:B-cell lymphoma-2 (BCL2) family proteins represent attractive therapeutic targets as they play an important role in MM cell survival. In patients with relapsed/refractory (R/R) MM harboring t(11;14) for whom multiple prior lines of therapy failed, single-agent venetoclax, a first generation BCL2 inhibitor, demonstrated antimyeloma activity (Kumar S, et al. Blood.2017). Dexamethasone, a long-standing mainstay of treatment for MM, increases the expression of both BCL2 and Bim. This results in a greater dependency on BCL2 for tumor survival, ultimately increasing the sensitivity to a BCL2 inhibitor.
Titel: |
Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose
|
---|---|
Autor/in / Beteiligte Person: | Quach, Hang ; Sborov, Doug ; Kazandjian, Dickran ; Spencer, Andrew ; Low, Michael ; Bal, Susan ; Callander, Natalie S. ; Cheng, Huan ; Patel, Sheel ; Crescenzo, Rocco J. ; Agarwal, Amit ; Dhakal, Binod |
Zeitschrift: | Blood, Jg. 142 (2023-11-28), Heft 1, Number 1 Supplement 1, S. 1011-1011 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 0006-4971 (print) ; 1528-0020 (print) |
DOI: | 10.1182/blood-2023-178735 |
Sonstiges: |
|